Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) – Pipeline Review, H2 2016’, provides in depth analysis on Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)

The report reviews Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

4SC AG

Chipscreen Biosciences Ltd

Curis, Inc.

GlaxoSmithKline Plc

HitGen LTD

IRBM Science Park SpA

Merck & Co., Inc.

Sigma-Tau S.p.A.

Syndax Pharmaceuticals Inc

TetraLogic Pharmaceuticals

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) Overview 7

Therapeutics Development 8

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Products under Development by Stage of Development 8

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Products under Development by Therapy Area 9

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Products under Development by Indication 10

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Products under Development by Companies 14

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Products under Development by Universities/Institutes 18

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Therapeutics Assessment 20

Assessment by Monotherapy/Combination Products 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Companies Involved in Therapeutics Development 25

4SC AG 25

Chipscreen Biosciences Ltd 26

Curis, Inc. 27

GlaxoSmithKline Plc 28

HitGen LTD 29

IRBM Science Park SpA 30

Merck & Co., Inc. 31

Sigma-Tau S.p.A. 32

Syndax Pharmaceuticals Inc 33

TetraLogic Pharmaceuticals 34

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Drug Profiles 35

4SC-202 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

CUDC-907 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Drug to Inhibit HDAC-3 for Oncology - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

entinostat - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

HG-3001 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

KDAC-0001 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Largazole - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

N-140 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

remetinostat - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecule to Inhibit Histone Deacetylases for Oncology - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

ST-3595 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

tucidinostat - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

vorinostat - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Dormant Projects 67

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Featured News & Press Releases 69

Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 69

Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 69

May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting 69

Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting 70

Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 71

Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 72

Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer 72

Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team 73

Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 73

Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting 74

Dec 03, 2015: Syndax Announces Multiple Data Presentations on Entinostat at Upcoming San Antonio Breast Cancer Symposium 75

Dec 01, 2015: Syndax Announces Initiation Of Entinostat Clinical Program In Japan By Partner Kyowa Hakko Kirin 76

Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting 77

Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata 77

Sep 30, 2015: 4SC receives funding from the Eurostars programme for further research of its anti-cancer agent 4SC-202 with an epigenetic mode of action 78

Appendix 79

Methodology 79

Coverage 79

Secondary Research 79

Primary Research 79

Expert Panel Validation 79

Contact Us 79

Disclaimer 80

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 (Contd..1) 16

Products under Development by Companies, H2 2016 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 24

Pipeline by 4SC AG, H2 2016 25

Pipeline by Chipscreen Biosciences Ltd, H2 2016 26

Pipeline by Curis, Inc., H2 2016 27

Pipeline by GlaxoSmithKline Plc, H2 2016 28

Pipeline by HitGen LTD, H2 2016 29

Pipeline by IRBM Science Park SpA, H2 2016 30

Pipeline by Merck & Co., Inc., H2 2016 31

Pipeline by Sigma-Tau S.p.A., H2 2016 32

Pipeline by Syndax Pharmaceuticals Inc, H2 2016 33

Pipeline by TetraLogic Pharmaceuticals, H2 2016 34

Dormant Projects, H2 2016 67

Dormant Projects (Contd..1), H2 2016 68

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 24

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports